

**P373**

**Activation of cannabinoid system by central angiotensin AT<sub>1</sub> and muscarinic receptors results in gastric mucosal defence in the rat.**

K. Gyires<sup>1</sup>, Z. Zádori<sup>1</sup>, J. Németh<sup>2</sup>, L. Hunyady<sup>3</sup>. <sup>1</sup>Semmelweis University, Department of Pharmacology and Pharmacotherapy 1089 Budapest, Hungary, <sup>2</sup>University of Debrecen, Department of Pharmacology and Pharmacotherapy 4032 Debrecen, Hungary, <sup>3</sup>Semmelweis University, Department of Physiology 1094 Budapest, Hungary

*Background:* Paracrine transactivation of CB<sub>1</sub> receptor by angiotensin AT<sub>1</sub> (and M<sub>1</sub>, M<sub>3</sub>, M<sub>5</sub>) receptors in Chinese hamster ovary cells was observed recently (Turu et al., J. Biol. Chem. 282, 7753, 2007; J. Biol. Chem. 284, 16914, 2009). Namely AT<sub>1</sub> (M<sub>1</sub>, M<sub>3</sub>, M<sub>5</sub>) receptors are Gq-protein-coupled receptor and activation of Gq/11 protein-coupled receptors results in activation of phospholipase C, which generates inositol-trisphosphate and diacylglycerol (DAG) from phosphatidylinositol (4,5)-bisphosphate. From DAG 2-arachidonoyl-glycerol (2-AG), an endocannabinoid is generated by diacylglycerol lipases (DAGLs).

*Aim:* To clarify, if angiotensin II (Ang II) can induce gastric mucosal protection by activation of endocannabinoid system. Namely, anandamide and synthetic cannabinoids were found to induce gastric mucosal protective effect given centrally, which was mediated by cannabinoid CB<sub>1</sub> receptors (Shujaa et al., J. Physiol. Pharmacol. 60 Suppl 7, 93-100).

*Method:* Gastric mucosal lesion was induced by acidified ethanol in male Wistar rats (140-170 g) and in CB<sub>1</sub> +/- and -/- mice after 24 h starvation. The mucosal lesions were examined 60 min after the ethanol challenge. The compounds were administered intracerebroventricularly (i.c.v.). The mucosal level of calcitonin-gene related peptides (CGRP) in the rat was determined by radioimmune assay.

*Results:* 1. Gastric mucosal protection could be induced both by exogenously injected cannabinoids, anandamide (2.9-115 nmol i.c.v.) and 2-AG (3.3-26.4 nmol i.c.v.) and by the inhibitors of their metabolizing enzymes, URB 597 (1.5-29.5 nmol i.c.v.) and JZL 184 (0.3-1.3 nmol i.c.v.). 2. Mucosal CGRP content decreased from 1.34 fmol/mg to 0.25 fmol/mg values 60 min after oral administration of ethanol and anandamide (58 nmol i.c.v.) and 2-AG (26.4 nmol i.c.v.) given 10 min before ethanol administration restored the ethanol-induced decrease of mucosal level of CGRP. 3. Ang II inhibited the ethanol-induced gastric mucosal lesions in a dose-dependent manner (0.012-0.19 nmol/rat i.c.v.); the effect was antagonized by both the AT<sub>1</sub> receptor antagonist candesartan (16 nmol) and the inverse agonist of CB<sub>1</sub> receptor, AM 251 (1.8 nmol). 4. Tetrahydrolipstatin (THL) (0.2 nmol i.c.v.), inhibitor of DAG lipase, enzyme is responsible for the formation of 2-AG, inhibited the gastroprotective effect of Ang II (0.19 nmol). 5. Ang II (0.19 nmol) exerted gastroprotective effect also in wild type mice, however, it was ineffective in CB<sub>1</sub> receptor KO mice. 6. Pilocarpine (35 nmol i.c.v.) also induced gastroprotective effect and both atropine and AM 251 reversed the protective action.

*Conclusion:* Activation of central angiotensin AT<sub>1</sub> or muscarinic receptors elicits gastroprotective action by stimulation of cannabinoid CB<sub>1</sub> receptors. Angiotensin AT<sub>1</sub> receptor-induced gastroprotective action is mediated via a DAGL-dependent mechanism.

The work was supported by TAMOP-4.2.1/B-09/1/KMR from the National Development Agency and OTKA-75965.